Mini-CAR BioSphere Platform

Caravan Biologix is at the forefront of innovation with our groundbreaking Mini-CARTM technology. Our technology offers a versatile platform solution for both our internal therapeutic development pipeline and limitless partnering opportunities with other biotechnology companies. Mini-CARs exhibit remarkable properties that include tissue honing, high target cell and tissue penetration, and multi-dosing options making them ideal for a wide range of applications.

​

One key advantage of Mini-CARs is their ability to evade cytotoxic responses during the course of treatment, including the inflammatory cytokine storm that is often associated with traditional whole cell CAR therapies. Moreover, the Mini-CARs excel at crossing tissue barriers and achieving focused targeting, leading to improved biodistribution and enhanced efficacy.

​​​

Additionally, Mini-CARs can be deployed as a co-therapeutic alongside whole-cell CAR therapies. While whole-cell CAR/TCR therapies have shown efficacy in clearing free-floating tumors, they have struggled against solid tumors. In this scenario, Mini-CARs could potentially ablate solid tumors from within, loosening them up for whole-cell CAR/TCR therapies to target and prevent systemic metastasis more effectively.

​

In summary, the Mini-CAR platform offers a revolutionary approach to CAR therapeutic development, with broad applications across various disease areas and a potential to transform the landscape of biotechnology.